Clinical trial
Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL
NCT00058617 · Baylor College of Medicine, Other · Completed
Key facts
| NCT number | NCT00058617 |
|---|---|
| Title | Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL |
| Official title | Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, EBV Positive Plasma Cell Neoplasm |
| Intervention type | Biological |
| Interventions | Injection of EBV Specific CTLs |
| Enrollment | 13 |
| Start date | Jan 1, 1996 |
| Primary completion | Aug 1, 2011 |
| Completion | Jul 1, 2014 |
| First posted | Apr 9, 2003 |
| Last update posted | Feb 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: